pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Neurology · news · pharmadog
← back to Neurology
News · Neurology
173
stories
21d
New funding, new jobs: 4 biotechs hiring after series B raises
biospace
21d
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
22d
FDA advisers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting
biospace
22d
FDA reviewers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting
biospace
22d
Caldera, Vidya add to recent flurry of biotech mergers
biopharma dive
22d
Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapy
biospace
23d
Opinion: STAT+: Dementia finally has a business model
stat
24d
MapLight’s schizophrenia drug disappoints once-daily hopes despite Phase 2 win
endpoints
24d
Otsuka’s ADHD approval opens up new drug class with $615M opportunity
biospace
24d
MapLight shares sink on mixed phase 2 schizophrenia readout
fiercebiotech
24d
From confidence to capital: Positioning biotech for the next growth cycle
biopharma dive
24d
Labcorp launches DTC ‘Genetic Health Panel’ to seek out multiple diseases
fiercebiotech
27d
CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
endpoints
27d
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
biospace
28d
Australian biopharma Clinuvel to shed up to 20% of workforce in move to US
fiercebiotech
Jul 21, 26
Jupiter enters psychedelics space with $100M deal for PharmAla's MDMA drug
fiercebiotech
Jul 20, 26
‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong
fiercebiotech
Jul 20, 26
How Kyverna rode CAR T’s autoimmune wave to the FDA’s door
biospace
Jul 17, 26
Biotronik Neuro snaps up spinal cord stimulation portfolio from Soin Neuroscience for next-gen pain project
fiercebiotech
Jul 15, 26
Why Axiom hopes it’s ‘solved 2 major potholes’ that have hurt other stem cell biotechs
fiercebiotech
Jul 9, 26
Roche ends work on tominersen after decade of trials, as well as early-stage Huntington’s asset
endpoints
Jul 9, 26
GSK walks away from Alector pact as immuno-neurology bet fizzles
endpoints
Jul 8, 26
Bryan Johnson’s chronic disease is notoriously difficult to diagnose
stat
Jul 8, 26
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal
biopharma dive
Jul 8, 26
Opinion: STAT+: What’s the right role for AI in dementia care?
stat
Jul 6, 26
Gene editing developer Scribe plots an IPO
biopharma dive
Jul 6, 26
Cancer, immune drugmakers dominate VC funding so far in 2026
biopharma dive
Jul 2, 26
Ex-iTeos CEO starts fresh at GSK neuro partner; Genentech loses yet another key scientist
endpoints
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 18, 26
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera
biopharma dive
← prev
page 2 of 6
next →
